30 Dec 2013 10:53
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Imperial Innovations Group Share News (IVO)
IVO Share
Price
IVO Share
News
IVO Share
Chat
IVO Share
Trades
IVO
Live RNS
IVO Share
Charts
IVO Broker
Ratings
IVO Directors
Deals
IVO Financial
Diary
IVO
Fundamentals
IVO Short
Positions
IVO
Media
Imperial Innovations Group Information
- There is currently no data for IVO
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Imperial Innovations' increases investments as pre-tax loss widens
Thu, 13th Oct 2016 08:36
(ShareCast News) - Imperial Innovations' annual pre-tax loss widened while the technology commercialisation and investment company increased investments across its business with universities and a joint venture.For the year ended 31 July, the pre-tax loss widened to £63.1m from £15.1m, last year, which included a £56.2m net fair value loss.Quoted net fair value loss of £66.9m was largely due to the decline in Circassia business share price due to a "disappointing" phase three trial for its cat allergy product which was why et assets only increased by 8.5% to £455.9m.During the year, the company invested £69.9m across 33 portfolio companies, a 15% increase in the rate of investment over previous year and more than double two years ago, due to an maturity of the portfolio companies.About 79% was invested into existing portfolio companies and seven growth companies were added to investment portfolio.The portfolio companies raised £206.4m, down 57%, while the net portfolio rose by 2.4% to £335.1m.There is £198.3m available to invest, including an undrawn £50m second loan facility from the European Investment Bank.The company committed £24.8m to the University College London Technology Fund and the European Investment Fund.Imperial Innovations allotted £3.3m to the $40m Apollo Therapeutics joint venture with Cambridge Enterprise, UCL Business, AstraZeneca, GlaxoSmithKline and Johnson & Johnson.Through a share placing on AIM the company raised £100m to strengthen the balance sheet.Chief executive Russ Cummings said: "We significantly increased our visibility of new investment opportunities and strengthened our position in our ecosystem with the elite universities within the 'Golden Triangle', with the completion of two new initiatives."Many of our portfolio companies made significant technical, clinical or commercial progress and we once again increased our level of investment, including leading six major funding rounds."We are continuing to see a healthy stream of new investment opportunities coming from the academic, research and entrepreneurial community within the 'Golden Triangle', as clearly demonstrated by the two new additions to our portfolio at the start of this new financial year."Shares in Imperial Innovations were by 0.61% to 415p at 0905 BST.
More News
17 Oct 2013 07:07
Thursday tips round-up: Imperial Innovations, Vertu Motors
Imperial Innovations has the right to take interesting discoveries from Imperial College London and package them up into companies that eventually can be floated or sold. The majority of its 92 investments are in pharmaceuticals; one of the most promising, Circassia, is well into clinical trials for
Read more16 Oct 2013 11:25
Imperial Innovations portfolio value rises as companies near IPO
Imperial Innovations accompanied news of a full year rise in its portfolio value with the announcement of a Nasdaq flotation for portfolio company Oxford Immunotec. The university spin-out group said had "a number" of companies in its portfolio also ready for initial public offering (IPO) or trade
Read more16 Oct 2013 10:36
17 Jul 2013 10:39
Innovations CEO steps down
Technology commercialisation and investment group Imperial Innovations confirmed that Chief Executive Susan Searle has stepped down after 11 years in the role. Chief investment officer Russ Cummings, who has been a director since the group's flotation in 2006, has taken over as CEO with immediate
Read more29 Apr 2013 12:15
Kelsey Lynn appointed Director of Technology Ventures at Imperial Innovations Group
AIM-listed technology commercialisation and investment group Imperial Innovations Group has reported that that Kelsey Lynn has joined as Director of Technology Ventures with immediate effect. Lynn spent the last twelve years in California, working in new technology development and venture capital
Read more22 Mar 2013 08:44
Imperial Innovations reports strong progress in top three portfolio companies
Imperial Innovations, a technology commercialisation and investment group, on Friday reported 'really good' progress in its top three portfolio companies in its half year results. The firm said that in the six months ended January 31st its top three portfolio companies, namely Circassia, Nexeon an
Read more22 Feb 2013 11:40
Imperial Innovations reports that Nexeon signed partnership with WACKER
AIM-listed technology commercialisation and investment group Imperial Innovations has announced that portfolio company Nexeon, a battery materials and licensing company, has signed a strategic partnership agreement with German chemical company WACKER Chemie AG (WACKER). The group reported that WAC
Read more23 Jan 2013 08:21
Imperial Innovations invests 1.5m pounds in tech firm Semetric
Technology commercialisation and investment group Imperial Innovations has invested 1.5m pounds in technology firm Semetric, the company behind global music analytics specialist, Musicmetric. The group said that the investment was part of a £3m funding round which also included its existing investo
Read more5 Oct 2012 13:18
Imperial Innovations rises to university challenge
A change in the fair value of investments held by Imperial Innovations, the hot-house for technology and healthcare ideas from Britain's universities, saw full year profits surge. Revenues eased, however, reflecting the continuing difficult economic environment. Total revenues in the year to the en
Read more